ReViral sets out clinical data timeline for RSV therapy

Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, chats with chief financial officer of ReViral Ltd., Max Herrmann, about the company's long-standing expertise in antiviral development and plans for the future. Recently RiViral managed to raise USD 21 million in a series A financing round that Herrmann explains will be spent on IND-enabling studies, first human studies and proof-of-concept trials for its leading RSV (respiratory syncytial virus) antiviral therapies.

[video src="https://www.youtube.com/embed/QMUm2L97FDY"]

Interviewer: Mike Ward – Global Director of Content, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: Max Herrmann – CFO, ReViral Ltd.